Dalton Investments was recently referenced in Bloomberg’s coverage of the emerging buyout wave among Japan’s pharmaceutical companies following Hisamitsu Pharmaceutical’s decision to go private in a management buyout. Dalton has actively encouraged portfolio companies, such as Aska Pharmaceutical, to evaluate strategic options that enhance long-term shareholder value. For further insight into Japan’s evolving pharmaceutical sector and the broader dynamics driving management buyouts, please access the article here. (Subscription required)
